< Back to situations

[ORGANIZATION]

Apogee Therapeutics

Featured in 2 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US]

AbbVie earnings and stock performance

2 clusters · 2 sources · last updated

Latest: Glenmede Trust Co. NA Cuts Stakes in Incyte and Williams‑Sonoma

In early July 2026 AbbVie’s shares slipped modestly even as analysts raised price targets, indicating a cautious market reaction despite optimistic forecasts. By the end of the month the company released its second‑quart

[ACTIVE] [BUSINESS] [HEALTH] [US] [CA] [FR]

Biopharma financing and deals 2026

22 clusters · 49 sources · last updated

Latest: AbbVie Q2 2026 earnings beat forecasts and announces Apogee Therapeutics acquisition

Throughout H1 2026, biotech financing and M&A accelerated. Early July saw French Abivax raise $800 m, United Therapeutics acquire Thymmune for $140 m, Vertex agree to buy Crinetics for $10 bn, and a series of partnership